Navigation Links
Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
Date:10/7/2009

CRANBURY, N.J., Oct. 7 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced today that groundbreaking cancer research scientist Robert A. Weinberg, Ph.D., a founding member of the Whitehead Institute for Biomedical Research and a Professor of Biology at MIT, has joined the company's Scientific Advisory Board.

Widely recognized for his discoveries of the first human oncogene (the ras oncogene that causes normal cells to form tumors), and the isolation of the first known tumor suppressor gene -- the Rb gene, Dr. Weinberg has long been recognized as a pioneer in cancer research.

"We are delighted to welcome Dr. Weinberg to our Scientific Advisory Board," commented Dr. Robert Shorr, CEO, of Cornerstone Pharmaceuticals. "Dr. Weinberg's accomplishments in cancer research are monumental and we believe his experience, guidance and vision will be of tremendous benefit to the Company."

Cornerstone Pharmaceuticals is currently recruiting patients with solid tumors to advance multiple Phase I/II human clinical trials of CPI-613, its lead drug to emerge from the company's Altered Energy Metabolism Directed (AEMD) technology platform. CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types. CPI-613 is being evaluated in a Phase I/II single agent trial for patients who have failed all other therapy as well as in a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients determined to be treated with gemcitabine. Pancreatic cancer, like many solid tumors, typically has a poor prognosis, spreads rapidly and often goes undetected in its early stages. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

"I am pleased to join Cornerstone Pharmaceuticals as a member of its Scientific Advisory Board and look forward to helping the Company develop vitally important potentially life-sustaining compounds that challenge and hopefully enhance conventional wisdom about treatment for a variety of cancers," said Dr. Weinberg. "Cornerstone is a leader in developing compounds that target the unique metabolic attributes of cancer cells. I believe, as do many others, that this is a promising area in cancer research, as this unique metabolism is essential to cancer cell survival and preserved across multiple cancer types."

Dr. Weinberg, who received his Ph.D. in biology from Massachusetts Institute of Technology in 1969, has also held research positions at the Weizmann Institute and the Salk Institute. He co-founded the Whitehead Institute and joined the MIT faculty as a professor of biology in 1982. That same year he published the landmark paper "Mechanism of Activation of a Human Oncogene" in the journal Nature. In 1999, he published "Creation of Human Tumor Cells with Defined Genetic Elements" also in Nature. Among his many distinctions, Dr. Weinberg was named "Scientist of the Year" by Discover magazine in 1982 and won the National Medal of Science in 1997 and the Otto Warburg Medal in 2007.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held pharmaceutical company singularly focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues. This unique approach, i.e. understanding and addressing what is similar to multiple cancer types rather than the differences between each, offers a significant opportunity to make a profound impact on the clinical treatment of a variety of cancers.

Cornerstone's AEMD technology platform was established on cancer metabolism research performed in the laboratories of Paul M. Bingham, Ph.D. and Zuzana Zachar, Ph.D., at the State University of New York at Stony Brook, Stony Brook, NY. Cornerstone has offices and laboratory facilities in both Cranbury, NJ. and Stony Brook, NY. For further information, please log onto http://www.cornerstonepharma.com.

About Whitehead Institute

Whitehead Institute for Biomedical Research is a leading, nonprofit research and educational institution that has defined the cutting edge of biomedical science, creating a legacy of research excellence and academic eminence since 1982. Wholly independent in its governance, finances and research programs, Whitehead shares a teaching affiliation with Massachusetts Institute of Technology (MIT), offering the intellectual, collegial and scientific benefits of a leading research university.

For further information or to arrange an interview with Cornerstone Pharmaceuticals senior management please contact Adam Mazur at (212) 843-8073 or email amazur@rubensteinpr.com.

SOURCE Cornerstone Pharmaceuticals, Inc.


'/>"/>
SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 In March, 2016, ... of free workshops across Africa ... for Good Distribution Practices (GDP). Good Distribution Practice ... products are consistently stored, transported and handled under suitable ... specification. Only a few years ago, there were ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute lymphocytic Leukemia ...  report to their offering.       ... Global Acute Lymphocytic Leukemia Market and Competitive ... Acute Lymphocytic Leukemia pipeline products, Acute Lymphocytic ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 2016 , ... Norwood Insurance Group, serving families of Dallas ... ongoing community enrichment program. The current campaign is being extended to continue fundraising ... months of treatments, leaving his family in great need of financial assistance. Donations ...
(Date:5/6/2016)... , ... May 06, 2016 , ... US Sports Camps ... rugby camp held at Oregon State University this summer. Employing world-class rugby figures, including ... of all skill levels with training on key fundamentals, match play, fitness and more. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate humidity ... is too cold, dry or hot, water on the eye surface can evaporate, creating ... the surrounding air. There’s only one problem, according to radio show and water advocate ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... The International ... Resort on the north end of the island close to the town famous for ... August 10th 2016. , “We continue to have an amazing experience in Greece, ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor ... education and corporate training, and the National Military Family Association, a nonprofit that ... as the second full-tuition scholarship recipient of 2016. , “Being awarded this ...
Breaking Medicine News(10 mins):